NCT05645315View on ClinicalTrials.gov

Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

April 28, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

June 30, 2024

Conditions
Advanced Solid Tumor
Interventions
DRUG

TQB2618 injection and TQB2450 injection

TQB2618 is a TIM-3 receptor monoclonal antibody; TQB2450 is a new sequence of innovative anti-PD-L1 fully humanized monoclonal antibody;

Trial Locations (5)

350014

NOT_YET_RECRUITING

Fujian Cancer Hospital, Fuzhou

410005

RECRUITING

Hunan Cancer Hospital, Changsha

430030

NOT_YET_RECRUITING

Tongji Hospital,Tongji Medical College of HUST, Wuhan

450000

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

610041

NOT_YET_RECRUITING

West China Hospital of Sichuan University, Chengdu

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY